Evaluating the safety and efficacy of Unani formulations in Psoriasis
Phase 2
- Conditions
- Health Condition 1: L409- Psoriasis, unspecified
- Registration Number
- CTRI/2024/06/068896
- Lead Sponsor
- ational Research Institute of Unani Medicine for Skin Disorders
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of any sex aged between 18-60 years of age,
Patients clinically diagnosed with Taqashshur al-Jild (Psoriasis),
Psoriasis area severity index (PASI) =10%.
Exclusion Criteria
Pregnant or Lactating Women,
Significant Pulmonary/Cardiovascular/ Hepato-renal Dysfunction,
Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies,
Patients with Psoriatic arthritis,
Erythrodermic psoriasis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method